A clinical trial is currently ongoing in the United States (NCT02498912) utilizing genetically modified T cells secreting IL-2 and targeting the MUC16ecto antigen in patients with recurrent high-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma-expressing MUC16ecto. Here, IL2 is linked to fallopian tube carcinoma.